Rafferty Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-59,207
| Closed | -$1.27M | – | 1147 |
|
|
2026
Q1 | $1.27M | Sell |
59,207
-97,803
| -62% | -$1.38M | 0.01% | 711 |
|
|
2025
Q4 | $1.46M | Buy |
157,010
+29,430
| +23% | +$246K | 0.01% | 720 |
|
|
2025
Q3 | $899K | Buy |
127,580
+28,889
| +29% | +$199K | ﹤0.01% | 816 |
|
|
2025
Q2 | $641K | Sell |
98,691
-20,469
| -17% | -$141K | ﹤0.01% | 838 |
|
|
2025
Q1 | $945K | Sell |
119,160
-40,248
| -25% | -$434K | ﹤0.01% | 754 |
|
|
2024
Q4 | $2.02M | Buy |
159,408
+22,975
| +17% | +$320K | 0.01% | 646 |
|
|
2024
Q3 | $1.9M | Sell |
136,433
-13,222
| -9% | -$189K | 0.01% | 650 |
|
|
2024
Q2 | $2.06M | Sell |
149,655
-43,569
| -23% | -$637K | 0.01% | 630 |
|
|
2024
Q1 | $3.19M | Sell |
193,224
-43,123
| -18% | -$645K | 0.01% | 562 |
|
|
2023
Q4 | $3.45M | Sell |
236,347
-737
| -0.3% | -$8.94K | 0.01% | 521 |
|
|
2023
Q3 | $2.91M | Sell |
237,084
-53,924
| -19% | -$703K | 0.02% | 504 |
|
|
2023
Q2 | $3.47M | Buy |
291,008
+99,563
| +52% | +$1.3M | 0.02% | 495 |
|
|
2023
Q1 | $2.56M | Sell |
191,445
-14,001
| -7% | -$273K | 0.02% | 538 |
|
|
2022
Q4 | $4.42M | Buy |
205,446
+60,812
| +42% | +$1.25M | 0.04% | 402 |
|
|
2022
Q3 | $2.9M | Buy |
+144,634
| New | +$3.08M | 0.03% | 425 |
|
Other funds holding DAWN
Rafferty Asset Management's DAWN Position: Q2 2026 in Review
Rafferty Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 59,207 shares — an estimated $1.27M sold.
Rafferty Asset Management first reported a position in DAWN in Q3 2022 and held it in 15 quarters. The position peaked at $4.42M in Q4 2022. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Rafferty Asset Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Rafferty Asset Management sold 59,207 Day One Biopharmaceuticals shares in Q2 2026, an estimated $1.27M.
- Rafferty Asset Management first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 15 quarters.
- Rafferty Asset Management's Day One Biopharmaceuticals position peaked at $4.42M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.